Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ever pharma jena gmbh - fulvestrant - solution for injection - 250mg/5ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fulvestrant 50 mg/ml;  ;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml     excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant ever pharma is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: · previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - fulvestrant 50 mg/ml - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml excipient: benzyl alcohol benzyl benzoate castor oil ethanol - fulvestrant-aft is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age previously treated with endocrine therapy (antioestrogen or aromatase inhibitor), irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

Israel - English - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

Israel - English - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

Israel - English - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapyfaslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy;or* with disease progression on endocrine therapy.combination therapy faslodex is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - fulvestrant, quantity: 50 mg/ml - injection, solution - excipient ingredients: ethanol; benzyl alcohol; benzyl benzoate; castor oil - faslodex is indicated for the treatment of postmenopausal women with:,? hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy.,? hr positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - fulvestrant - fulvestrant....250 mg.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios laprin, s.a. - fulvestrant - fulvestrant....50,00 mg

Singapore - English - HSA (Health Sciences Authority)

sandoz singapore pte. ltd. - fulvestrant - injection, solution - fulvestrant 250mg/5ml